A Double-blind, Phase 1, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 May 2018
At a glance
- Drugs BOS 161721 (Primary) ; BOS 161721 (Primary)
- Indications Autoimmune disorders; Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Boston Pharmaceuticals
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Oct 2017 Planned End Date changed from 1 Apr 2018 to 12 Apr 2018.